25 LLC’s Takeda Pharmaceutical TAK Stock Holding History

25 LLC’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-18	Closed	-$279	–	499
2023 Q2	$279	Hold	18	–	–	﹤0.01%	603
2023 Q1	$299	Buy	+18	New	+$287	﹤0.01%	496

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

25 LLC's TAK Position: Q3 2023 in Review

25 LLC sold out of Takeda Pharmaceutical (TAK) in Q3 2023, closing a stake of 18 shares — an estimated $279 sold.

25 LLC first reported a position in TAK in Q1 2023 and held it in 2 quarters. The position peaked at $299 in Q1 2023. 312 funds tracked by Wall St. Rank hold TAK as of Q3 2023.

25 LLC reported no remaining Takeda Pharmaceutical position as of Q3 2023 after selling out during the quarter.
25 LLC sold 18 Takeda Pharmaceutical shares in Q3 2023, an estimated $279.
25 LLC first reported a position in Takeda Pharmaceutical in Q1 2023 and held it in 2 quarters.
25 LLC's Takeda Pharmaceutical position peaked at $299 in Q1 2023.
312 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q3 2023.

Based on 25 LLC's 13F filing for Q3 2023, filed 18 Oct 2023.